Genfit is a biopharmaceutical company engaged in the discovery and development of drugs and biomarkers in therapeutic areas of high unmet need due to the lack of effective treatments or diagnostic tools and/or due to the increasing number of patients worldwide. Co. concentrates its research and development efforts to participate in the commercialization of treatment solutions and diagnostic tools to fight certain metabolic, inflammatory, autoimmune or fibrotic diseases affecting especially the liver (such as non-alcoholic steatohepatitis or "NASH").
  • TickerALGFT
  • ISINFR0004163111
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Matthieu DRIOL

Short term view - GENFIT : Rising consolidation.

The background trend is clearly bearish. The negative MACD confirms the trend. The rise is a consolidation that will soon bump against the level at €21.90. The next target is at €17.80, then €16.50. Passing €28.28 would question the continuation of the fall.

Matthieu DRIOL

Analyse court terme - GENFIT : La reprise est une consolidation.

La tendance de fond est clairement orientée à la baisse. Le MACD est négatif, il confirme cette tendance. La reprise est une consolidation qui va buter sur 21,90 € prochainement. Le prochain objectif est à 17,80 €, puis 16,50 €. Le franchissement de 28,28 € remettrait en cause la suite de la baisse.

Matthieu DRIOL

Short term view - GENFIT : Falling prices.

The background trend is clearly bearish. Prices are falling again, but the movement has become hesitant. The next support is at €17.80. The background trend would be questioned should prices rise above €28.28.

Matthieu DRIOL

Analyse court terme - GENFIT : Les prix baissent.

La tendance de fond est clairement orientée à la baisse. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 17,80 €. La tendance de fond serait remise en cause en cas de franchissement de 28,28 €.

Matthieu DRIOL

Medium term view - GENFIT : The movement goes on.

The background trend is clearly bearish. The movement goes on. The next target is at €16.30, then €6.74. Passing €35.59 would question the continuation of the fall.

Jean-Jacques Le Fur

GENFIT | BUY, FV EUR65 |NASH Is King

Genfit a future leader in NASH. Genfit is due to release phase III data for elafibranor in NASH next year. The market is untapped with no available drugs and could reach USD10-15bn. Following Phase III results, elafibranor is set to be part of the first wave of drug launches as its main competitor Ocaliva (Intercept). However, the later has some side effects that we consider incompatible with chronic treatment and for this reason, we expect elafibranor to rapidly take the majority of prescriptions. The speed of this uptake will depend on changes in NASH diagnosis, which currently involves bio...

Charles Lepetitpas ...
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Hana Maalej
  • Harold De Decker
  • Jean Sassus
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Nicolas David
  • Oussema Denguir
  • Pierre Corby
  • Stephane Houri
  • Steven Gould
  • Veysel Taze

ODDO BHF Small & MIDCAP MORNING NEWS - 09/13/2018

...

Charles Lepetitpas ...
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Hana Maalej
  • Harold De Decker
  • Jean Sassus
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Nicolas David
  • Oussema Denguir
  • Pierre Corby
  • Stephane Houri
  • Steven Gould
  • Veysel Taze

ODDO BHF Small & MIDCAP MORNING NEWS - 13/09/2018

...

Oussema Denguir ...
  • Pierre Corby

Genfit : NASH: Elafibranor one of the three front-runners

Recent months have seen ample clinical newsflow for NASH, the new metabolic “fatty liver” disease. NASH could become a significant market over the coming years (>$ 15bn-$ 20bn) and competition is beginning to heat up. We have reviewed the groups which have made the greatest progress: Genfit is among the leading three, but its valuation is 4.5x less expensive than its peers! Buy recommendation reiterated. Target price lifted to € 59 vs € 46. - >Will 2019 be NASH’s year? Res...

Oussema Denguir ...
  • Pierre Corby

Genfit : NASH : Elafibranor dans le trio de tête !

Les derniers mois ont été riches en données cliniques dans la NASH, cette nouvelle maladie métabolique du “foie gras”. La NASH pourrait être un marché très important d’ici quelques années (>15/20 Md$) et la concurrence commence à faire rage. Nous faisons le point sur les acteurs les plus avancés : Genfit ressort dans le trio de tête pour 4.5x moins cher que ses pairs ! Achat réitéré. OC relevé à 59 € (vs 46 €). - >2019, l’année de la NASH : 4 résultats d’études pivotales - ...

A director bought 83,333 shares at 22.200EUR and

A director at Genfit bought 83,333 shares at 22.200EUR and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board...

GENFIT sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of GENFIT (FR), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date September 25, 2018, the closing price was EUR 21.60 and its target price was estimated at EUR 19.97.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Jehanne Leroy

Proxy Report - 15/06/2018

Alors même que la société recueillait l’an dernier des taux d’approbation assez faibles sur ses autorisations financières, principalement en raison de leur maintien en période d’offre publique, elle réitère cette année, sourde à la contestation de ses actionnaires. Ainsi, comme l’année dernière, Proxinvest ne soutiendra pas ces autorisations, non seulement en raison du maintien en période d’offre publique, mais également en raison des montants demandés dans le cas des autorisations sans DPS. De la même façon, alors que la plupart des sociétés du SBF120 proposent des rémunérations sous forme d...

Matthieu DRIOL

Short term view - GENFIT : Rising consolidation.

The background trend is clearly bearish. The negative MACD confirms the trend. The rise is a consolidation that will soon bump against the level at €21.90. The next target is at €17.80, then €16.50. Passing €28.28 would question the continuation of the fall.

Matthieu DRIOL

Analyse court terme - GENFIT : La reprise est une consolidation.

La tendance de fond est clairement orientée à la baisse. Le MACD est négatif, il confirme cette tendance. La reprise est une consolidation qui va buter sur 21,90 € prochainement. Le prochain objectif est à 17,80 €, puis 16,50 €. Le franchissement de 28,28 € remettrait en cause la suite de la baisse.

Matthieu DRIOL

Short term view - GENFIT : Falling prices.

The background trend is clearly bearish. Prices are falling again, but the movement has become hesitant. The next support is at €17.80. The background trend would be questioned should prices rise above €28.28.

Matthieu DRIOL

Analyse court terme - GENFIT : Les prix baissent.

La tendance de fond est clairement orientée à la baisse. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 17,80 €. La tendance de fond serait remise en cause en cas de franchissement de 28,28 €.

Matthieu DRIOL

Medium term view - GENFIT : The movement goes on.

The background trend is clearly bearish. The movement goes on. The next target is at €16.30, then €6.74. Passing €35.59 would question the continuation of the fall.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch